Correct Answer : AstraZeneca
Trial data from AstraZeneca on 20-08-2021 raised the prospect of a new treatment to prevent COVID-19 beyond vaccines, giving hope in particular for people who respond poorly to immunisation shots.
AstraZeneca, a UK-based biopharmaceutical company, on August 20, 2021, announced that its PROVENT Phase-III prophylaxis trial of its antibody cocktail therapy AZD7442, a combination of two long-acting antibodies (LAAB), met the primary goal of preventing COVID-19 in late-stage cases.